The Authors’ Reply

David R. Head(University of Southern California), G. Bennett Humphrey(St. Jude Children's Research Hospital), Catherine Craven(University of Utah), Lizardo Cerezo(Orlando Regional Medical Center), Michael J. Borowitz(Johns Hopkins University), John M. Falletta(Orlando Regional Medical Center), James M. Boyett(University of Illinois Chicago), D. Jeanette Pullen, William M. Crist(St. Jude Children's Research Hospital), Brenda L. Brock(St. Jude Children's Research Hospital)
American Journal of Clinical Pathology
March 1, 1988
10.1093/ajcp/89.3.452
Cited by 2

Related Papers

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study
|Blood|2000|1.6k
Deletion of <i>IKZF1</i> and Prognosis in Acute Lymphoblastic Leukemia
|New England Journal of Medicine|2009|1.4k
Age and acute myeloid leukemia
|Blood|2006|1.4k